PROMIS-29在系统性硬化症中的性能:SPIN队列研究
该研究基于SPIN队列中696例系统性硬化症患者,检验PROMIS-29v2的聚合效度并探索临床关联。9条假设中7条支持效度(|r|=0.51-0.87,P<0.001)。胃肠道受累与全部8个领域显著更差相关,关节挛缩与7个领域显著下降相关。
要点
- PROMIS-29v2在SSc中聚合效度良好,9条假设中7条得到支持。
- 胃肠道受累与全部8个PROMIS-29v2领域显著更差相关。
- 关节挛缩与7个领域显著下降相关,效应量小至中等。
核心结论
- 本研究进一步确立PROMIS-29v2在SSc中的效度,并强调胃肠道症状和关节挛缩对健康相关生活质量下降的重要性。
研究设计与样本
- 研究纳入加拿大、美国、英国26个中心的SPIN队列中英语SSc患者,于2014年7月至2015年11月完成PROMIS-29v2,入组医生提供医疗数据。
主要发现
- 共696例患者(87%女性),平均(s.d.)病程11.6(8.7)年,57%为局限皮肤型亚型。
- 效度指标与9条假设中的7条一致(|r|=0.51-0.87,P<0.001),2条假设有轻微偏差。
- 胃肠道受累与全部8个PROMIS-29v2领域显著更差结局相关,其中6个领域效应量为中等或中到大。
- 关节挛缩与7个领域显著下降相关,效应量为小或小到中等。
- 皮肤增厚、弥漫皮肤型亚型和重叠综合征与5或6个领域显著相关,效应量为小或小到中等。
关键数值与推荐
- 效应量标注:小(<0.25)、小到中等(0.25-0.45)、中等(0.46-0.55)、中到大(0.56-0.75)、大(>0.75)。
临床怎么用
- PROMIS-29v2可用于SSc患者健康相关生活质量的评估,尤其应关注胃肠道症状和关节挛缩对生活质量的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Patient-Reported Outcomes Measurement Information System (PROMIS)-29 assesses seven health-related quality of life domains plus pain intensity. The objective was to examine PROMIS-29v2 validity and explore clinical associations in patients with SSc. METHODS: English-speaking SSc patients in the Scleroderma Patient-centered Intervention Network Cohort from 26 sites in Canada, the USA and the UK completed the PROMIS-29v2 between July 2014 and November 2015. Enrolling physicians provided medical data. To examine convergent validity, hypotheses on the direction and magnitude of correlations with legacy measures were tested. For clinical associations, t -tests were conducted for dichotomous variables and PROMIS-29v2 domain scores. Effect sizes (ESs) were labelled as small (<0.25), small to moderate (0.25-0.45), moderate (0.46-0.55), moderate to large (0.56-0.75) and large (>0.75). RESULTS: There were 696 patients (87% female), mean ( s . d .) disease duration 11.6 (8.7) years, 57% with limited cutaneous subtype. Validity indices were consistent with seven of nine hypotheses (| r | =0.51-0.87, P < 0.001), with minor divergence for two hypotheses. Gastrointestinal involvement was associated with significantly worse outcomes for all eight PROMIS-29v2 domains (moderate or moderate to large ES in six of eight). Presence of joint contractures was associated with significant decrements in seven domains (small or small to moderate ESs). Skin thickening, diffuse cutaneous subtype and presence of overlap syndromes were significantly associated (small or small to moderate ESs) with five or six domains. CONCLUSION: This study further establishes the validity of the PROMIS-29v2 in SSc and underlines the importance of gastrointestinal symptoms and joint contractures in reduced health-related quality of life.
引用
- Kwakkenbos L, Thombs BD, Khanna D, et al. Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. Rheumatology (Oxford). 2017. PMID: 28431140. doi:10.1093/rheumatology/kex055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。